ODAC Proves a Harsh Critic of Amgen's Xgeva in CRPC
"Show me the benefit" was the mantra Wednesday when an FDA advisory committee critiqued the ability of Amgen Inc.'s Xgeva to prolong the time until bone metastasis in men with castration-resistant prostate cancer.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter